Refine Search
(0)
(0)
(0)
(3)

Legitimising Stem Cell Therapies

Stem cell technology holds the potential to revolutionise healthcare as we know it. As this technology has the ability to regenerate complex tissue of all types, it appears possible that revolutionary treatments for diseases that currently have no cure can be developed. As the gaps between new stem cell therapies and regulatory bodies are bridged, GlobalData expects that new and exciting therapeutic options will become available and their subsequent markets will open.

EpiCast Report: Multiple Sclerosis – Epidemiology Forecast to 2026

  • $3,995
  • November 2017
Add to Basket Quick View Add to Saved List

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. To forecast the diagnosed prevalent and diagnosed incident cases of ...

EpiCast Report: Age-Related Macular Degeneration – Epidemiology Forecast to 2026

  • $3,995
  • November 2017
Add to Basket Quick View Add to Saved List

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant ...

Macular Degeneration Global Clinical Trials Review, H2, 2017

  • $2,500
  • November 2017
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Macular Degeneration Global Clinical Trials Review, H2, 2017" provides an overview of Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trial...

Multiple Sclerosis Global Clinical Trials Review, H2, 2016

  • $2,500
  • July 2016
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Multiple Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on...